ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 A Phase 1b/2 Study of the BET Inhibitor ZEN-3694 in Combination With Talazoparib for Treatment of Patients With TNBC Without gBRCA1/2 Mutations
By
ASCO 2022 Conference Coverage
FEATURING
Philippe Aftimos
By
ASCO 2022 Conference Coverage
FEATURING
Philippe Aftimos
27 views
July 26, 2022
Login to view comments.
Click here to Login
Breast